Evolva completes Allylix acquisition

December 16, 2014 | Tuesday | News | By BioSpectrum Bureau

Evolva completes Allylix acquisition

Allylix will be a wholly-owned subsidiary of Evolva

Allylix will be a wholly-owned subsidiary of Evolva

Evolva Holding announces the completion of the acquisition of Allylix, after which the aquired comapany will be a wholly-owned subsidiary of Evolva.

This transaction is in return for an overall consideration of 46 million newly-issued Evolva shares (c. 14.1 percent of Evolva post transaction). Part of these shares, currently estimated at approx. 6 million shares, will be sold over a period of time after closing, to offset certain liabilities and transaction expenses of Allylix. Shares allocated to the Allylix security holders will be subject to a staggered lock-up, such that the shares will be released in twelve tranches of approx. 3 million shares each, during the first year after the closing of the transaction.

The SIX Swiss Exchange has approved the listing of the new Evolva shares and trading in the new shares on the Main Standard of SIX is expected to commence soon.

 

 

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy